On Tuesday, Vertex Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 85.
IBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
Decades of market research reveals that the best-performing stocks often have an 80 or higher RS Rating as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
The IBD 50 stock is trying to complete a consolidation with a 519.88 buy point. See if the stock can break out in volume at least 40% above average.
While EPS growth dropped last quarter from 7% to -5%, sales grew 16%, up from 12% in the prior report.
The company holds the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics and Krystal Biotech are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
